Physician profile
Daniel Mwanza
NPI 1275827826
$6,767.76
in general payments reported to CMS, 2019-2025
10 companies · $418 in 2025
The $418 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.25 · 2022: $242 · 2023: $2,014 · 2024: $4,076 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,051 · Education: $1,500 · Food and Beverage: $869 · Long Term Medical Supply Or Device Loan: $87.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,051.08 |
| Education | $1,500.00 |
| Food and Beverage | $869.31 |
| Long Term Medical Supply Or Device Loan | $87.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,303.19 | 2023-2024 | Da Vinci Surgical System |
| Zimmer Biomet Holdings, INC. | $1,429.64 | 2023 | Advantagerib |
| Integra Lifesciences Corporation | $329.12 | 2022-2025 | Micromatrix |
| Acera Surgical, INC. | $227.78 | 2023-2025 | Restrata Wound Matrix |
| Ceribell, INC. | $180.19 | 2023 | Ceribell Rapid Response Eeg |
| Smith+Nephew, INC. | $117.48 | 2025 | Pico 14 |
| Ethicon US, LLC | $96.38 | 2023 | Echelon; Endopath, Enseal, Echelon Endopath |
| Vertex Pharmaceuticals Incorporated | $47.93 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.25 | 2021 | |
| Kls-Martin L.P. | $17.80 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mwanza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.